Tag: MK-3000
-
Merck’s Remigromig Meets Phase 2b/3 Endpoint in Diabetic Macular Edema
Both remigromig doses were noninferior to ranibizumab at Week 52 in the Phase 2b/3 BRUNELLO trial, but safety imbalances and commercial differentiation require further data.